Wed, Aug 5, 2015
A A A
Welcome Guest
Free Trial RSS
Get FREE trial access to our award winning publications
Alternative Market Briefing

Apple & Allergan top list of hedge fund positions

Wednesday, August 27, 2014

Bailey McCann, Opalesque New York:

S&P Capital IQ is out with its quarterly hedge fund tracker, ranking the positions of pure play hedge funds based on reported data including Form 13F. Report data finds that information technology and healthcare stocks saw the largest growth in new hedge fund buying activity during Q2 2014, with Allergan and Apple as the most popular individual stocks.

On a sector basis, IT stocks saw hedge fund flows of $1.45 billion leading the pack for the second quarter in a row. Healthcare was at second most popular, for the top 10 hedge funds with $1.4 billion. Financials down $2.25 billion, with a decrease in American International Group $686 and Crown Castle International $272.

Allergan Inc. was the top new buy among the largest 10 hedge funds with $1.43 billion in new positions, 6 funds holding it; 2 brand new funds bought the company, 2 increasing existing positions and 2 held their stake. The company is being aggressively pursued by Valeant Pharmaceuticals Intl Inc. (VRX) and Pershing Square Capital Management LP for a takeover.

Apple saw the second-highest level of new buying activity among hedge funds with $855 million in new buys in Q2. Last quarter it was the second top buy with $1.95 billion bought, but, also the second top sell with $871 million sold. This quarter, we see no such ambivalence. Also listing the top 100 po......................

To view our full article Click here

Today's Exclusives Today's Other Voices More Exclusives
Previous Opalesque Exclusives                                  
More Other Voices
Previous Other Voices                                               
Access Alternative Market Briefing


  • Top Forwarded
  • Top Tracked
  • Top Searched
  1. Activist News - Celgene says patent-fighting hedge fund manager wants to short its shares[more]

    From Reuters.com: Celgene Corp, one of the world's largest biotechnology companies, has accused U.S. hedge fund manager Kyle Bass of attempting to profit from his attempts to wipe out several major drug patents through his Coalition for Affordable Drugs. The company asked the U.S. Patent and T

  2. Einhorn's Greenlight Capital hedge fund slumps 6.1 percent in July[more]

    From Reuters/Thefiscaltimes.com: Hedge fund mogul David Einhorn's Greenlight Capital slumped 6.1 percent in July and is now down 9 percent for the year after gold, one of the fund's top holdings, tumbled to five-year lows last week. Greenlight notified clients of its returns late on Friday, ac

  3. Performance - Some hedge fund small-cap energy stocks have been free falling, Dan Loeb's simple strategy destroys the market, Baupost lost 1.4% last quarter as energy bargains proved elusive[more]

    Some hedge fund small-cap energy stocks have been free falling From Marketrealist.com: According to a July 28, 2015, Bloomberg article, there was a 34% fall in small-cap energy stocks over the past three months. These shares are tracked by the Russell 2000 Energy Index. Small-cap energy

  4. Legal - Hedge funds hit Rothstein Kass with $75m malpractice suit, JPMorgan questioned on private bank’s hedge fund disclosures, Kijani fund, seized by regulators in Cayman Islands, spotlights risks in lightly regulated market[more]

    Hedge funds hit Rothstein Kass with $75m malpractice suit From Law360.com: Two investment funds have sued Rothstein Kass & Co. PC for at least $75 million, claiming the New Jersey auditing firm committed accounting malpractice by failing to properly scrutinize overblown valuations of the

  5. Assets - Hedge funds are getting smoked by the commodities slump, Global ETF assets could more than double by 2020[more]

    Hedge funds are getting smoked by the commodities slump From Businessinsider.in: The collapse in commodity prices has burnt another hedge fund. Vermillion, a commodity hedge fund backed by Carlyle Group, has seen its flagship fund's assets fall from nearly $2 billion to less $50 million,

 

banner